146.93

0.24% -0.35

Neurocrine Biosciences Inc (NBIX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Storia dei dividendi

Precedente Chiudi:

$147.28

Aprire:

$148.17

Volume 24 ore:

359.68K

Relative Volume:

0.36

Capitalizzazione di mercato:

$14.65B

Reddito:

$2.41B

Utile/perdita netta:

$305.80M

Rapporto P/E:

49.81

EPS:

2.95

Flusso di cassa netto:

$492.20M

1 W Prestazione:

+3.69%

1M Prestazione:

+4.02%

6M Prestazione:

+14.63%

1 anno Prestazione:

+7.62%

Intervallo 1D:

$146.53

$148.38

Intervallo di 1 settimana:

$141.00

$148.56

Portata 52W:

$84.23

$160.18

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Nome

Neurocrine Biosciences Inc

Settore

Healthcare (1130)

Industria

Drug Manufacturers - Specialty & Generic (84)

Telefono

(858) 617-7600

Indirizzo

6027 EDGEWOOD BEND COURT, SAN DIEGO, CA

Dipendente

1,800

Cinguettio

Prossima data di guadagno

2024-10-30

Ultimi documenti SEC

NBIX's Discussions on Twitter

Confronta NBIX con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
NBIX Neurocrine Biosciences Inc	146.93	14.68B	2.41B	305.80M	492.20M	2.95
ZTS Zoetis Inc	125.49	54.44B	9.40B	2.65B	2.24B	5.935
TAK Takeda Pharmaceutical Co Adr	15.58	48.84B	29.63B	260.53M	5.51B	0.0788
HLN Haleon Plc Adr	10.10	45.02B	14.26B	1.98B	2.47B	0.4327
TEVA Teva Pharmaceutical Industries Ltd Adr	31.74	36.19B	16.88B	666.71M	251.19M	0.6132
UTHR United Therapeutics Corp	514.64	21.98B	3.08B	1.24B	1.07B	25.61

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-10-21	Iniziato	Citigroup	Buy
2025-07-21	Iniziato	Truist	Buy
2025-07-10	Iniziato	Goldman	Buy
2025-04-15	Aggiornamento	Needham	Hold → Buy
2025-04-14	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2025-02-11	Iniziato	Deutsche Bank	Hold
2024-10-10	Ripresa	Raymond James	Outperform
2024-08-29	Aggiornamento	Piper Sandler	Neutral → Overweight
2024-04-24	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2023-12-13	Ripresa	Citigroup	Neutral
2023-12-12	Iniziato	Deutsche Bank	Buy
2023-10-24	Ripresa	Cantor Fitzgerald	Overweight
2023-08-21	Reiterato	Mizuho	Neutral
2023-07-24	Aggiornamento	SVB Securities	Market Perform → Outperform
2023-07-06	Aggiornamento	BMO Capital Markets	Underperform → Market Perform
2023-05-04	Aggiornamento	Guggenheim	Neutral → Buy
2023-03-30	Aggiornamento	Canaccord Genuity	Hold → Buy
2023-03-03	Aggiornamento	Evercore ISI	In-line → Outperform
2023-02-03	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2022-11-14	Downgrade	Evercore ISI	Outperform → In-line
2022-10-11	Iniziato	UBS	Buy
2022-09-26	Iniziato	Wells Fargo	Equal Weight
2022-06-06	Ripresa	Jefferies	Buy
2022-03-03	Downgrade	Piper Sandler	Overweight → Neutral
2022-02-25	Aggiornamento	Goldman	Neutral → Buy
2022-01-18	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2021-11-19	Iniziato	BMO Capital Markets	Underperform
2021-11-17	Aggiornamento	JP Morgan	Neutral → Overweight
2021-10-14	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2021-09-23	Ripresa	Needham	Hold
2021-08-06	Downgrade	Canaccord Genuity	Buy → Hold
2021-05-18	Ripresa	Goldman	Neutral
2021-05-06	Aggiornamento	Barclays	Equal Weight → Overweight
2021-02-02	Iniziato	Raymond James	Outperform
2020-09-30	Iniziato	The Benchmark Company	Hold
2020-08-04	Downgrade	JP Morgan	Overweight → Neutral
2020-06-29	Downgrade	Goldman	Buy → Neutral
2020-06-09	Iniziato	Wedbush	Outperform
2020-03-06	Iniziato	Citigroup	Buy
2020-02-27	Iniziato	Barclays	Equal Weight
2020-02-24	Iniziato	William Blair	Outperform
2020-02-06	Iniziato	Mizuho	Neutral
2020-02-05	Reiterato	H.C. Wainwright	Buy
2019-12-13	Downgrade	Credit Suisse	Outperform → Neutral
2019-08-07	Iniziato	RBC Capital Mkts	Outperform
2019-07-16	Iniziato	Oppenheimer	Outperform
2019-06-05	Iniziato	Guggenheim	Neutral
2019-05-21	Iniziato	Credit Suisse	Outperform
2019-04-22	Aggiornamento	JP Morgan	Neutral → Overweight
2019-04-12	Iniziato	Evercore ISI	Outperform
2019-02-06	Reiterato	BofA/Merrill	Buy
2019-01-23	Downgrade	JP Morgan	Overweight → Neutral
2018-12-13	Iniziato	Goldman	Buy
2018-11-21	Iniziato	Canaccord Genuity	Buy

Mostra tutto

Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie

06:17 AM

Swedbank AB Has $76.83 Million Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

06:17 AM

Dec 24, 2025

Neurocrine Biosciences (NBIX) Stock News: Brighton Jones Raises Stake to $1.43M - Eudaimonia and Co

Dec 24, 2025

Brighton Jones LLC Has $1.43 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Dec 24, 2025

Dec 23, 2025

AbbVie, Neurocrine End One Orilissa Patent Case Against Hetero - Bloomberg Law News

Dec 23, 2025

Voya Investment Management LLC Cuts Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Dec 23, 2025

What's Going On With Neurocrine Biosciences Stock Tuesday?Neurocrine Biosciences (NASDAQ:NBIX) - Benzinga

Dec 23, 2025

Neurocrine’s valbenazine misses Phase III goals in DCP - The Pharma Letter

Dec 23, 2025

Neurocrine Biosciences (NBIX): Assessing Valuation After New Phase 2 Bipolar I Mania Trial Launch - Sahm

Dec 23, 2025

Dec 22, 2025

Neurocrine : Phase 3 Study Of Valbenazine In Dyskinetic Cerebral Palsy Fails To Meet Main Goal - Nasdaq

Dec 22, 2025

Neurocrine's movement disorder treatment fails late-stage trial - marketscreener.com

Dec 22, 2025

Neurocrine's Phase 3 Trial of Valbenazine in Dyskinetic Cerebral Palsy Fails to Meet Primary, Key Secondary Endpoints - marketscreener.com

Dec 22, 2025

Neurocrine’s phase 3 trial for cerebral palsy drug fails to meet endpoints - Investing.com

Dec 22, 2025

Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy - PR Newswire

Dec 22, 2025

Assenagon Asset Management S.A. Sells 13,280 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Dec 22, 2025

Dec 21, 2025

Neurocrine’s Ingrezza Keeps Growing, But The Stock Has Lagged - Finimize

Dec 21, 2025

Dec 20, 2025

What hedge fund activity signals for Neurocrine Biosciences Inc. stock2025 Valuation Update & Weekly Sector Rotation Insights - Bölüm Sonu Canavarı

Dec 20, 2025

How Neurocrine Biosciences Inc. stock valuations compare to rivals2025 Volatility Report & Fast Gaining Stock Reports - Улправда

Dec 20, 2025

Dec 19, 2025

Merger Talk: Can Neurocrine Biosciences Inc. stock beat analyst upgrades2025 EndofYear Setup & Risk Managed Investment Entry Signals - moha.gov.vn

Dec 19, 2025

Is Neurocrine Biosciences (NBIX) Quietly Recasting Its Long-Term Story Around Metabolic Disease Innovation? - simplywall.st

Dec 19, 2025

How Neurocrine Biosciences Inc. (NB3) stock reacts to monetary easing2025 Earnings Surprises & Low Risk Entry Point Tips - ulpravda.ru

Dec 19, 2025

How Neurocrine Biosciences Inc. stock performs in weak economyQuarterly Earnings Summary & Weekly Hot Stock Watchlists - Улправда

Dec 19, 2025

Nxera Knocked Back As Boehringer Bows Out Of Schizophrenia Pact - Citeline News & Insights

Dec 19, 2025

Is Neurocrine Biosciences Inc. (NB3) stock a momentum leaderPortfolio Gains Summary & Technical Pattern Recognition Alerts - DonanımHaber

Dec 19, 2025

Why Neurocrine Biosciences Inc. stock is favored by pension fundsQuarterly Market Summary & Growth Focused Entry Point Reports - DonanımHaber

Dec 19, 2025

Dec 18, 2025

Neurocrine Bio. stock price target raised to $198 by H.C. Wainwright - Investing.com Canada

Dec 18, 2025

Published on: 2025-12-18 16:31:37 - Улправда

Dec 18, 2025

RBC Capital Keeps Their Buy Rating on Neurocrine (NBIX) - The Globe and Mail

Dec 18, 2025

Dec 17, 2025

HC Wainwright & Co. Maintains Neurocrine Biosciences (NBIX) Buy Recommendation - Nasdaq

Dec 17, 2025

Neurocrine Biosciences (NASDAQ:NBIX) Director Leslie Norwalk Sells 1,190 Shares - MarketBeat

Dec 17, 2025

Neurocrine Biosciences (NASDAQ:NBIX) Director Leslie Norwalk Sells 5,000 Shares - MarketBeat

Dec 17, 2025

Neurocrine Biosciences Director Sells Shares - TradingView — Track All Markets

Dec 17, 2025

Neurocrine Bio. stock price target reiterated at $200 by TD Cowen - Investing.com Canada

Dec 17, 2025

Key facts: HC Wainwright maintains 'Buy' on Neurocrine; price target rises - TradingView — Track All Markets

Dec 17, 2025

Neurocrine Bio. stock holds Buy rating at Jefferies after R&D Day - Investing.com Canada

Dec 17, 2025

Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat

Dec 17, 2025

Neurocrine Bio. stock rating reiterated at Outperform by RBC Capital - Investing.com Canada

Dec 17, 2025

Texas Permanent School Fund Corp Sells 11,976 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Dec 17, 2025

Neurocrine showcases R&D across neuroscience and endocrinology - The Pharma Letter

Dec 17, 2025

Neurocrine Bio. stock holds steady as BMO reiterates $147 price target - Investing.com UK

Dec 17, 2025

Dec 16, 2025

Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology - PR Newswire

Dec 16, 2025

Dec 15, 2025

What analysts say about Neurocrine Biosciences Inc stockMomentum Trading Signals & Free Daily Top Stock Picks for All Investors - earlytimes.in

Dec 15, 2025

Dir Norwalk Files To Sell 11,250 Of Neurocrine Biosciences Inc [NBIX] - TradingView — Track All Markets

Dec 15, 2025

Hudson Bay Capital Management LP Has $9.75 Million Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Dec 15, 2025

Dec 14, 2025

Neurocrine Biosciences (NBIX): Revisiting Valuation After a Year of Double-Digit Shareholder Returns - simplywall.st

Dec 14, 2025

Thrivent Financial for Lutherans Cuts Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Dec 14, 2025

Dec 13, 2025

Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Expected to Rise, Mizuho Analyst Says - MarketBeat

Dec 13, 2025

Boone Capital Management LLC Makes New Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Dec 13, 2025